This study systematically analyzed data from the FAERS database, covering from Q1 2004 to Q2 2024, to investigate reports of cholecystitis and cholelithiasis in which GLP-1 RAs were identified as the primary suspect drug. Here, GLP1R is linked to cholelithiasis.